{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "CDC_Influenza_vaccines",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": false,
    "additional_count": 0
  },
  "completeness_stats": {
    "existing_evidence": 2,
    "new_evidence_found": 0,
    "total_evidence": 2
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "Flublok Quadrivalent (Sanofi Pasteur) 0.5 mL PFS \u226518 yrs 45 \u00b5g/0.5 mL IM",
      "relevance_explanation": "This quote identifies Flublok Quadrivalent as a vaccine product, specifying its manufacturer, dosage, and age indication, which is necessary context for understanding its evaluation in clinical trials."
    },
    {
      "id": 2,
      "quote": "Fluarix Quadrivalent (standard-dose vaccine)",
      "relevance_explanation": "This quote identifies Fluarix Quadrivalent as a standard-dose comparator vaccine, which is relevant to the claim that Flublok Quadrivalent was evaluated against it in a pivotal trial."
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}